MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably
Director of Health Research at Assistance-Publique Hôpitaux de Marseille (AP-HM) since June 2018, I wish to strengthen Marseille’s position in clinical research. To achieve this, I have relied on the willingness of the management team. It has been essential to structure and increase the internal resources of the AP-HM in terms of research, methodology and promotion of trials.
Even at the size of the AP-HM, or perhaps because of its size, external collaborations are essential to boost clinical research. I would have liked to participate in the exciting adventure that must have been creating Marseille Immunopôle, this breeding ground for ideas and projects. I was able to appreciate its interest through the engagement of Marseille’s university hospitals in all sorts of projects (Future Investment Project, The Pioneer Project RHU, the FEDER project, and partnership projects with industry).
I accepted the proposal of Marseille Immunopôle to lead with them the EXPLORE COVID-19 project, from the very beginning of the health crisis. Our proven partnership allows us to act with complete confidence in an emergency. It is the assurance that the best scientists are mobilized to serve patients within the rigorous regulatory framework of clinical research. Following an initial study on the immune response to the SARS-CoV-2 infection, our collaboration has further strengthened with the launch of FORCE (FOR Covid Elimination), a double-blind, randomized therapeutic clinical trial, 28 days after the launch of EXPLORE COVID-19. With hard work and respect for everyone’s skills, we were able to offer physicians an innovative treatment for patients with severe forms of the disease in record time.#clinique
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
AMU, Gustave Roussy, The Pioneer Project
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
AMU, IPC, CRCM
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.